Logo image of SXTP

60 DEGREES PHARMA INC (SXTP) Stock Fundamental Analysis

USA - NASDAQ:SXTP - US83006G4010 - Common Stock

1.42 USD
-0.01 (-0.7%)
Last: 10/3/2025, 8:06:08 PM
1.42 USD
0 (0%)
After Hours: 10/3/2025, 8:06:08 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SXTP. SXTP was compared to 197 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SXTP have multiple concerns. While showing a medium growth rate, SXTP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SXTP had negative earnings in the past year.
SXTP had a negative operating cash flow in the past year.
In the past 5 years SXTP always reported negative net income.
SXTP had a negative operating cash flow in each of the past 5 years.
SXTP Yearly Net Income VS EBIT VS OCF VS FCFSXTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

The Return On Assets of SXTP (-198.65%) is worse than 88.83% of its industry peers.
SXTP's Return On Equity of -342.13% is on the low side compared to the rest of the industry. SXTP is outperformed by 74.62% of its industry peers.
Industry RankSector Rank
ROA -198.65%
ROE -342.13%
ROIC N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SXTP Yearly ROA, ROE, ROICSXTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

SXTP has a better Gross Margin (63.74%) than 71.07% of its industry peers.
SXTP's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SXTP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
SXTP Yearly Profit, Operating, Gross MarginsSXTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

3

2. Health

2.1 Basic Checks

SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SXTP has more shares outstanding
Compared to 1 year ago, SXTP has a worse debt to assets ratio.
SXTP Yearly Shares OutstandingSXTP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
SXTP Yearly Total Debt VS Total AssetsSXTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

SXTP has an Altman-Z score of -18.02. This is a bad value and indicates that SXTP is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -18.02, SXTP is not doing good in the industry: 80.20% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.06 indicates that SXTP is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.06, SXTP perfoms like the industry average, outperforming 52.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -18.02
ROIC/WACCN/A
WACC9.84%
SXTP Yearly LT Debt VS Equity VS FCFSXTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 2.27 indicates that SXTP has no problem at all paying its short term obligations.
The Current ratio of SXTP (2.27) is comparable to the rest of the industry.
A Quick Ratio of 1.80 indicates that SXTP should not have too much problems paying its short term obligations.
The Quick ratio of SXTP (1.80) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 1.8
SXTP Yearly Current Assets VS Current LiabilitesSXTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

5

3. Growth

3.1 Past

SXTP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -512.57%.
The Revenue has grown by 120.64% in the past year. This is a very strong growth!
The Revenue for SXTP have been decreasing by -52.49% on average. This is quite bad
EPS 1Y (TTM)-512.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.09%
Revenue 1Y (TTM)120.64%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%146.3%

3.2 Future

SXTP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.73% yearly.
Based on estimates for the next years, SXTP will show a very strong growth in Revenue. The Revenue will grow by 82.46% on average per year.
EPS Next Y94.26%
EPS Next 2Y38.52%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue Next Year94.66%
Revenue Next 2Y88.83%
Revenue Next 3Y82.46%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SXTP Yearly Revenue VS EstimatesSXTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
SXTP Yearly EPS VS EstimatesSXTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SXTP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SXTP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTP Price Earnings VS Forward Price EarningsSXTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTP Per share dataSXTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as SXTP's earnings are expected to grow with 25.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.52%
EPS Next 3Y25.73%

More info and screens

0

5. Dividend

5.1 Amount

SXTP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

60 DEGREES PHARMA INC

NASDAQ:SXTP (10/3/2025, 8:06:08 PM)

After market: 1.42 0 (0%)

1.42

-0.01 (-0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/dmh
Earnings (Next)N/A N/A
Inst Owners11%
Inst Owner Change0%
Ins Owners1.2%
Ins Owner Change0.44%
Market Cap5.82M
Analysts80
Price Target7.14 (402.82%)
Short Float %2%
Short Ratio0.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.98%
Min EPS beat(2)-27.66%
Max EPS beat(2)-16.31%
EPS beat(4)0
Avg EPS beat(4)-80.11%
Min EPS beat(4)-247.17%
Max EPS beat(4)-16.31%
EPS beat(8)1
Avg EPS beat(8)-42.74%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.66%
Min Revenue beat(2)-29.6%
Max Revenue beat(2)0.28%
Revenue beat(4)1
Avg Revenue beat(4)-19.46%
Min Revenue beat(4)-45.31%
Max Revenue beat(4)0.28%
Revenue beat(8)1
Avg Revenue beat(8)-27.25%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)20.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.29%
EPS NY rev (1m)0%
EPS NY rev (3m)42.44%
Revenue NQ rev (1m)8.55%
Revenue NQ rev (3m)8.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.98
P/FCF N/A
P/OCF N/A
P/B 2.4
P/tB 2.55
EV/EBITDA N/A
EPS(TTM)-21.66
EYN/A
EPS(NY)-3.11
Fwd EYN/A
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0.24
BVpS0.59
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -198.65%
ROE -342.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.74%
FCFM N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
F-Score3
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 145.9%
Cap/Sales 10.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 1.8
Altman-Z -18.02
F-Score3
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)258.14%
Cap/Depr(5y)228.76%
Cap/Sales(3y)28.01%
Cap/Sales(5y)17.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-512.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.09%
EPS Next Y94.26%
EPS Next 2Y38.52%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue 1Y (TTM)120.64%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%146.3%
Revenue Next Year94.66%
Revenue Next 2Y88.83%
Revenue Next 3Y82.46%
Revenue Next 5YN/A
EBIT growth 1Y13.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.33%
OCF growth 3YN/A
OCF growth 5YN/A